I am planning to establish a Scopolamine Model of Alzheimer's Disease to test novel therapeutics. My lit review suggested Scopolamine should be administered 1-3 mg/kg for 4 to 7 days prior to behavioral testing. As positive control, I will challenge the scopolamine with Donepezil it appears 0.1mg/kg is very effective in reversing deficits caused by scopolamine.

Behavioral tests with include y-maze and novel object recognition.

Does anyone with experience with this model care to share their basic design?

More David Hubbard's questions See All
Similar questions and discussions